A Precise Approach to Treating Prostate Cancer: Focal Therapy Program Expands at Mount Sinai
Mount Sinai is expanding its use of an image-guided technology that focuses on removing only cancerous tissue in the prostate, sparing the rest of the gland. The technique presents a contrast to traditional approaches, where removing the entire prostate leaves patients safe from cancer, but facing profound sexual and urinary side effects.
Focal therapy is a technique of treating only the cancerous areas of the prostate, not affecting the rest of the prostate. The focal therapy program at Mount Sinai will be the first to use fusion biopsy technology to deliver treatment more precisely. Fusion-guided biopsy, an imaging technique which combines MRI and ultrasound imaging to better visualize the prostate during procedures, has been in use at Mount Sinai since 2013 for use in obtaining biopsy samples.
The newly expanded program will be led by Art R. Rastinehad, DO, Director of Focal Therapy and Interventional Urologic Oncology and Associate Professor of Urology and Radiology at the Icahn School of Medicine at Mount Sinai. Dr. Rastinehad, who joined Mount Sinai from the North Shore-LIJ Health System in January, is a recognized leader in the design of the imaging and the screening techniques at the foundation of focal therapy. In collaboration with the National Cancer Institute and Philips Health care, for instance, Dr. Rastinehad helped to develop the first fusion biopsy device.
“We are extremely pleased to welcome Dr. Rastinehad to Mount Sinai,” said Ash Tewari, MD, the Kyung Hyun Kim, MD Chair of Urology at the Mount Sinai Health System and Professor of Urology at the Icahn School of Medicine at Mount Sinai. “I look forward to working with Art to further develop our focal therapy initiative.”
Dr. Rastinehad is the first dual fellowship trained urological oncologist to practice interventional urology. In his new position, he will work with other industry leaders at the Icahn School of Medicine at Mount Sinai to advance a multidisciplinary approach to treating prostate cancer.
Since joining the Mount Sinai Health System, Dr. Rastinehad led the first international course on MRI/US fusion guided biopsies, sponsored by the American Urological Association and hosted at the Icahn School of Medicine at Mount Sinai in December of last year. Dr. Rastinehad will lead future courses at Mount Sinai including one held in March. For more information, visit https://www.auanet.org/education/courses/MRFUS151.
About the Mount Sinai Health System
The Mount Sinai Health System is New York City's largest integrated delivery system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai's vision is to produce the safest care, the highest quality, the highest satisfaction, the best access and the best value of any health system in the nation. The Health System includes approximately 7,480 primary and specialty care physicians; 11 joint-venture ambulatory surgery centers; more than 410 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and 31 affiliated community health centers. The Icahn School of Medicine is one of three medical schools that have earned distinction by multiple indicators: ranked in the top 20 by U.S. News & World Report's "Best Medical Schools", aligned with a U.S. News & World Report's "Honor Roll" Hospital, No. 12 in the nation for National Institutes of Health funding, and among the top 10 most innovative research institutions as ranked by the journal Nature in its Nature Innovation Index. This reflects a special level of excellence in education, clinical practice, and research. The Mount Sinai Hospital is ranked No. 14 on U.S. News & World Report's "Honor Roll" of top U.S. hospitals; it is one of the nation's top 20 hospitals in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Geriatrics, Gynecology, Nephrology, Neurology/Neurosurgery, and Orthopedics in the 2019-2020 "Best Hospitals" issue. Mount Sinai's Kravis Children's Hospital also is ranked nationally in five out of ten pediatric specialties by U.S. News & World Report. The New York Eye and Ear Infirmary of Mount Sinai is ranked 12th nationally for Ophthalmology, Mount Sinai St. Lukes and Mount Sinai West are ranked 23rd nationally for Nephrology and 25th for Diabetes/Endocrinology, and Mount Sinai South Nassau is ranked 35th nationally for Urology. Mount Sinai Beth Israel, Mount Sinai St. Luke's, Mount Sinai West, and Mount Sinai South Nassau are ranked regionally.